Combination of the novel ERK inhibitor AZD0364 with the MEK inhibitor selumetinib significantly enhances antitumor activity in KRAS mutant tumor models

被引：0

作者：

Flemington, Vikki ^{[1
]}

Simpson, Iain ^{[1
]}

Breed, Jason ^{[1
]}

Davies, Emma ^{[1
]}

Gibbons, Francis ^{[2
]}

Hopcroft, Phillip ^{[1
]}

Lyndsay, Nicola ^{[1
]}

Jones, Christopher ^{[3
]}

Jones, Clifford ^{[4
]}

Robinson, David ^{[1
]}

Rooney, Claire ^{[1
]}

Roberts, Karen ^{[1
]}

Sandin, Linda ^{[1
]}

Ward, Richard ^{[1
]}

Zhang, Pei ^{[1
]}

Pease, Elizabeth ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] AstraZeneca, Waltham, MA USA

[3] Lundbeck, Copenhagen, Denmark

[4] RedX Pharma, Macclesfield, Cheshire, England

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-1856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1856

引用

页数：2

共 50 条

[1] AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Flemington, Vikki
Davies, Emma J.
Robinson, David
Sandin, Linda C.
Delpuech, Oona
Zhang, Pei
Hanson, Lyndsey
Farrington, Paul
Bell, Sigourney
Falenta, Katarzyna
Gibbons, Francis D.
Lindsay, Nicola
Smith, Aaron
Wilson, Joanne
Roberts, Karen
Tonge, Michael
Hopcroft, Philip
Willis, Sophie E.
Roudier, Martine P.
Rooney, Claire
Coker, Elizabeth A.
Jaaks, Patricia
Garnett, Mathew J.
Fawell, Stephen E.
Jones, Clifford D.
Ward, Richard A.
Simpson, Iain
Cosulich, Sabina C.
Pease, J. Elizabeth
Smith, Paul D.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (02) : 238 - 249
[2] Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models
Merchant, M.
Chan, J.
Orr, C.
Cheng, J.
Wang, X.
Hunsaker, T.
Wagle, M. C.
Huang, S. A.
Tremayne, J.
Ngu, H.
Solon, M.
Eastham-Anderson, J.
Koeppen, H.
Friedman, L.
Belvin, M.
Moffat, J.
Junttila, M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 124 - 124
[3] Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC
Simpson, Iain
Anderton, Mark J.
Andrews, David M.
Breed, Jason
Davies, Emma
Debreczeni, Judit E.
Flemington, Vikki
Gibbons, Francis D.
Graham, Mark A.
Hopcroft, Philip
Howard, Tina
Hudson, Julian
Jones, Clifford D.
Jones, Christopher
Lindsay, Nicola
Pease, J. Elizabeth
Rawlins, Philip
Roberts, Karen
Swallow, Steve
St-Gallay, Steve
Tonge, Michael E.
Ward, Richard A.
CANCER RESEARCH, 2018, 78 (13)
[4] Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells
Lim, Sun Min
Hwang, Jee Won
Ahn, Joong Bae
Bae, Soo Kyung
Park, Chan Hee
Kim, Ki-Yeol
Rha, Sun Young
Chung, Hyun Cheol
Roh, Jae Kyung
Shin, Sang Joon
ANTICANCER RESEARCH, 2013, 33 (06) : 2499 - 2508
[5] RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Yuan, Xi
Zhang, Xinwen
Du, Rong
Cheung, Shing-Hu
Wei, Min
Zhou, Changyou
Wang, Lai
Shearer, Todd
Edris, Badreddin
Smith, Mary
Yao, Zhan
Thant, Claire N.
Rosen, Neal
Luo, Lusong
CANCER RESEARCH, 2020, 80 (16)
[6] Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Ward, Richard A.
Anderton, Mark J.
Bethel, Paul
Breed, Jason
Cook, Calum
Davies, Emma J.
Dobson, Andrew
Dong, Zhiqiang
Fairley, Gary
Farrington, Paul
Feron, Lyman
Flemington, Vikki
Gibbons, Francis D.
Graham, Mark A.
Greenwood, Ryan
Hanson, Lyndsey
Hopcroft, Philip
Howells, Rachel
Hudson, Julian
James, Michael
Jones, Clifford D.
Jones, Christopher R.
Li, Yongchao
Lamont, Scott
Lewis, Richard
Lindsay, Nicola
McCabe, James
McGuire, Thomas
Rawlins, Philip
Roberts, Karen
Sandin, Linda
Simpson, Iain
Swallow, Steve
Tang, Jia
Tomkinson, Gary
Tonge, Michael
Wang, Zhenhua
Zhai, Baochang
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (24) : 11004 - 11018
[7] Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
Pia Morelli, M.
Tentler, John J.
Kulikowski, Gillian N.
Tan, Aik-Choon
Bradshaw-Pierce, Erica L.
Pitts, Todd M.
Brown, Amy M.
Nallapareddy, Sujatha
Arcaroli, John J.
Serkova, Natalie J.
Hidalgo, Manuel
Ciardiello, Fortunato
Gail Eckhardt, S.
CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1051 - 1062
[8] Anti-tumor activity of a TBK1/IKBKE inhibitor in combination with a MEK inhibitor in KRAS mutant colorectal and non-small cell lung cancer models
Stinson, S.
He, J.
Hollenback, D.
Jia, J.
Kaplan, J.
Venkataramani, C.
Babusis, D.
Guevara, F.
Nelson, T.
Cavanaugh, J.
Asahina, H.
Ray, A.
Sicinska, E.
Fuchs, C.
Barbie, D.
Wong, K. K.
Ng, K.
Dornan, D.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S146 - S146
[9] HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor
Choi, Jaeyul
Jumg, Seung Hyun
Park, Wongi
Byun, Jooyun
Lim, Semi
Lee, Youngjoo
Jeon, Soye
Kim, Yu-Yon
Ahn, Young Gil
Kim, Young Hoon
Suh, Kwee Hyun
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[10] The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
Zou, Yun
Wang, Jianfeng
Leng, Xuejiao
Huang, Jiwei
Xue, Wei
Zhang, Jin
Huang, Yiran
ONCOTARGET, 2017, 8 (13) : 20825 - 20833

← 1 2 3 4 5 →